168 related articles for article (PubMed ID: 33991401)
1. Adolescent-adult nonmetastatic Ewing sarcoma-Experience from a large developing country.
Bajpai J; Panda GS; Chandrasekharan A; Bhargava P; Srinivas S; Laskar S; Dandekar S; Mokal S; Rekhi B; Khanna N; Menon N; Patil V; Noronha V; Joshi A; Prabhash K; Banavali SD; Gupta S
Pediatr Blood Cancer; 2021 Sep; 68(9):e29081. PubMed ID: 33991401
[TBL] [Abstract][Full Text] [Related]
2. Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol.
Ferrari S; Sundby Hall K; Luksch R; Tienghi A; Wiebe T; Fagioli F; Alvegard TA; Brach Del Prever A; Tamburini A; Alberghini M; Gandola L; Mercuri M; Capanna R; Mapelli S; Prete A; Carli M; Picci P; Barbieri E; Bacci G; Smeland S
Ann Oncol; 2011 May; 22(5):1221-1227. PubMed ID: 21059639
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Brennan B; Kirton L; Marec-Bérard P; Gaspar N; Laurence V; Martín-Broto J; Sastre A; Gelderblom H; Owens C; Fenwick N; Strauss S; Moroz V; Whelan J; Wheatley K
Lancet; 2022 Oct; 400(10362):1513-1521. PubMed ID: 36522207
[TBL] [Abstract][Full Text] [Related]
4. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.
Wagner MJ; Gopalakrishnan V; Ravi V; Livingston JA; Conley AP; Araujo D; Somaiah N; Zarzour MA; Ratan R; Wang WL; Patel SR; Lazar A; Ludwig JA; Benjamin RS
Oncologist; 2017 Oct; 22(10):1271-1277. PubMed ID: 28710342
[TBL] [Abstract][Full Text] [Related]
5. Analysis of bone and soft-tissue sarcomas registered during the year 2012 at Tata Memorial Hospital, Mumbai, with clinical outcomes.
Bajpai J; Khanna N; Vora T; Gulia A; Laskar S; Puri A; Sanduptla B; Chinnaswamy G; Nayak P; Juvekar SL; Janu A; Desai S; Ghosh J; Purandare N; Ramadwar M; Rangarajan V; Rekhi B
Indian J Cancer; 2018; 55(1):37-44. PubMed ID: 30147091
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide.
Lu E; Ryan CW; Bassale S; Lim JY; Davis LE
Oncologist; 2020 Feb; 25(2):150-155. PubMed ID: 32043790
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.
Le Deley MC; Paulussen M; Lewis I; Brennan B; Ranft A; Whelan J; Le Teuff G; Michon J; Ladenstein R; Marec-Bérard P; van den Berg H; Hjorth L; Wheatley K; Judson I; Juergens H; Craft A; Oberlin O; Dirksen U
J Clin Oncol; 2014 Aug; 32(23):2440-8. PubMed ID: 24982464
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.
Salah S; Abuhijla F; Ismail T; Yaser S; Sultan I; Halalsheh H; Shehadeh A; Abdelal S; Almousa A; Jaber O; Abu-Hijlih R
Clin Transl Oncol; 2020 Jun; 22(6):878-883. PubMed ID: 31429039
[TBL] [Abstract][Full Text] [Related]
9. VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors.
El Weshi A; Memon M; Raja M; Bazarbashi S; Rahal M; El Foudeh M; Pai C; Allam A; El Hassan I; Ezzat A
Am J Clin Oncol; 2004 Oct; 27(5):529-34. PubMed ID: 15596925
[TBL] [Abstract][Full Text] [Related]
10. Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study.
Ferrari S; Palmerini E; Alberghini M; Staals E; Mercuri M; Barbieri E; Longhi A; Cantero L; Cesari M; Abate M; Balladelli A; Picci P; Bacci G
Tumori; 2010; 96(2):213-8. PubMed ID: 20572576
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
[TBL] [Abstract][Full Text] [Related]
12. Extraskeletal Ewing sarcoma in children, adolescents, and young adults. An analysis of three prospective studies of the Cooperative Weichteilsarkomstudiengruppe (CWS).
Koscielniak E; Sparber-Sauer M; Scheer M; Vokuhl C; Kazanowska B; Ladenstein R; Niggli F; Ljungman G; Paulussen M; Bielack SS; Seitz G; Fuchs J; Hallmen E; Klingebiel T; On Behalf Of The Cws Study Group
Pediatr Blood Cancer; 2021 Oct; 68(10):e29145. PubMed ID: 34089219
[TBL] [Abstract][Full Text] [Related]
13. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and survival of 92 cases of Ewing's sarcoma family of tumor initially treated with multidisciplinary therapy].
Peng RJ; Sun XF; Xiang XJ; Zhen ZJ; Ling JY; Tong GL; Xia Y; Xu GC; Jiang WQ
Ai Zheng; 2009 Dec; 28(12):1304-9. PubMed ID: 19958626
[TBL] [Abstract][Full Text] [Related]
15. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
[TBL] [Abstract][Full Text] [Related]
16. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.
Granowetter L; Womer R; Devidas M; Krailo M; Wang C; Bernstein M; Marina N; Leavey P; Gebhardt M; Healey J; Shamberger RC; Goorin A; Miser J; Meyer J; Arndt CA; Sailer S; Marcus K; Perlman E; Dickman P; Grier HE
J Clin Oncol; 2009 May; 27(15):2536-41. PubMed ID: 19349548
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
Brunetto AL; Castillo LA; Petrilli AS; Macedo CD; Boldrini E; Costa C; Almeida MT; Kirst D; Rodriguez-Galindo C; Pereira WV; Watanabe FM; Pizza M; Benites E; Morais V; Gadelha A; Nakasato A; Abujamra AL; Gregianin LJ;
Pediatr Blood Cancer; 2015 Oct; 62(10):1747-53. PubMed ID: 25917418
[TBL] [Abstract][Full Text] [Related]
18. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Kushner BH; Meyers PA
J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
[TBL] [Abstract][Full Text] [Related]
19. Challenges in the management of localized Ewing sarcoma in a developing country.
Totadri S; Bansal D; Rao KLN; Jain R; Saxena AK; Kapoor R; Samujh R; Trehan A
Pediatr Hematol Oncol; 2020 Oct; 37(7):610-619. PubMed ID: 32558608
[TBL] [Abstract][Full Text] [Related]
20. Ewing Sarcoma: A 15-Year Experience of a Single Center With the MSKCC P6 Treatment Protocol.
Ben-Ami T; Waldman E; Marc W; Weintraub M; Revel-Vilk S; Fried I
J Pediatr Hematol Oncol; 2016 Jan; 38(1):38-42. PubMed ID: 26670840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
